Abbott (ABT) announced it has received CE Mark in Europe for an expanded indication for the company’s Navitor transcatheter aortic valve implantation system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. Abbott previously received CE Mark in 2021 for Navitor to treat people with symptomatic, severe aortic stenosis who are at high or extreme surgical risk. With this new approval, Navitor is available in Europe for patients across all surgical risk categories, significantly expanding the number of people that can be treated with the device.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Unusually active option classes on open August 21st
- Insider Sales: D-Wave, AGNC, BigBearai, Abbott, Etsy
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
- Abbott put volume heavy and directionally bearish
- Reckitt Lawsuit Alert! Class Action Lawsuit Against Reckitt Benckiser Group